| Identification | Back Directory | [Name]
LY2623091 | [CAS]
1162264-07-4 | [Synonyms]
LY2623091 LY2623091
(LY-2623091 Urea, N-[5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]-2H-benzimidazol-2-ylidene]-, [N(E)]- | [Molecular Formula]
C30H30FN5O3 | [MDL Number]
MFCD26406001 | [MOL File]
1162264-07-4.mol | [Molecular Weight]
527.6 |
| Hazard Information | Back Directory | [Uses]
LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors[1][2]. | [References]
[1] Dickinson G L, et al. Physiologically based pharmacokinetic modeling to understand the observed drug–drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem[J]. International journal of Pharmacokinetics, 2017, 2(4): 233-245. [2] Kocienski P. Synthesis of LY2623091[J]. Synfacts, 2017, 13(05): 0451. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|